Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients


Phase N/A Results N/A

Trial Description

Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya disease and stroke patients

Detailed Description

In the early hours following large vessel occlusion, the ultimate severity of the stroke is largely determined by the ability of collateral flow networks to supply blood to ischemic tissue via circuitous routes that bypass the proximal clot. Robust collateral flow can improve response to thrombolytic therapy and decrease the risk of intracranial hemorrhage. Despite their central importance, collaterals during acute stroke are poorly understood, largely because assessment has required an invasive imaging test, cerebral angiography. This proposal assesses whether a noncontrast MRI perfusion technique, called arterial spin labeling (ASL), can yield important information about collateral flow.



  • Xenon as contrast agent Drug
    Other Names: XeMED contrast agent
    ARM 1: Kind: Experimental
    Label: Moyamoya, acute stroke, other
    Description: Approximately 210 participants will be enrolled, including the following groups: 60 Moyamoya patients, 60 acute stroke patients, 30 healthy participants and 60 patients with diagnosis unspecified

Trial Design

  • Masking: Open Label
  • Purpose: Diagnostic
  • Intervention: Single Group Assignment
  • Observation: Cohort
  • Perspective: Prospective


Type Measure Time Frame Safety Issue
Primary Arterial spin labeling in magnetic resonance imaging to assess collateral blood flow performed one time prior to surgery No